Lv21
168 积分 2025-01-02 加入
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
1小时前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
1个月前
已完结
Target Trial Emulation for Regulatory and Clinical Decision Making in Cancer
6个月前
已完结
Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR- mutated non-small cell lung cancer: systematic review and network meta-analysis
7个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
1年前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1年前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
1年前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
1年前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
1年前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
1年前
已完结
皖公网安备34019202002308
